Book demo
Log in
Companies
Biotest
Logotype for Biotest Aktiengesellschaft

Biotest (BIO3) investor relations material

Biotest has been delisted

Biotest Q1 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Biotest Aktiengesellschaft
Q1 2025 earnings summary12 May, 2025

Executive summary

  • Q1 2025 revenue fell 42.3% year-over-year to €124.2 million, mainly due to a sharp drop in technology transfer revenue from Grifols and lower product sales.

  • EBIT declined to €-23.0 million from €52.8 million in Q1 2024, reflecting reduced sales and lower earnings from technology services.

  • Net loss after taxes was €-21.4 million, compared to a profit of €29.5 million in the prior year period.

  • Product sales of human albumin and Yimmugo® increased by 17.0% and 10.2% respectively, despite overall product sales decline.

  • Biotest completed Phase III trials for fibrinogen and advanced regulatory filings in Europe and the US.

Financial highlights

  • Revenue: €124.2 million (Q1 2025) vs €215.2 million (Q1 2024), down 42.3%.

  • EBIT: €-23.0 million (Q1 2025) vs €52.8 million (Q1 2024).

  • Net loss: €-21.4 million (Q1 2025) vs net income €29.5 million (Q1 2024).

  • EPS: €-0.55 (Q1 2025) vs €0.74 (Q1 2024).

  • Operating cash flow: €-58.1 million (Q1 2025) vs €-11.6 million (Q1 2024).

Outlook and guidance

  • 2025 sales expected to decline mid single-digit percent from 2024, reflecting lower technology transfer revenue.

  • EBIT forecasted between €-55.0 million and €-75.0 million for 2025.

  • ROCE expected between -3% and -7%; operating cash flow anticipated to remain negative.

  • Risks include Middle East conflict, potential US tariffs on EU pharmaceuticals, and FDA response delays.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.
Latest events from Biotest
View more events
Companies
Biotest
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Related articles
Winner, Winner: The Chicken McNugget Story
Edge
16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Six decades of McDonald's growth, counted in restaurants
Visuals
16 Oct 2026
McDonald's systemwide restaurant growth
Public in 1965, McNuggets by 1983, and still growing in 2025
Visuals
16 Oct 2026
McDonald's EPS expansion

Frequently asked questions

Biotest Aktiengesellschaft is a German-based company that specializes in the development, production, and marketing of plasma proteins and biological drugs. The company’s primary focus areas include clinical immunology, hematology, and intensive care medicine. Biotest’s product portfolio includes immunoglobulins, coagulation factors, and albumins, which are derived from human blood plasma and are utilized in treating immune and hematopoietic system disorders. Additionally, the company engages in the development of monoclonal antibodies for treating conditions such as cancer of plasma cells and systemic lupus erythematosus. The company is headquartered in Dreieich, Germany, and its shares are listed on the Frankfurt Stock Exchange.